Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Gene Therapy for Rare Disease Market Expected to Surpass US$ 2087.6 Million by 2032 with a CAGR of 36.6%

This image opens in the lightbox

News provided by

Prophecy Market Insights

11 May, 2023, 10:45 GMT

Share this article

Share toX

Share this article

Share toX

COVINA, Calif., May 11, 2023 /PRNewswire/ -- According to Prophecy Market Insights ""Gene Therapy for Rare Disease Market accounted for US$ 78.4 Million in 2022 and is estimated to be US$ 2087.6 Million by 2032 and is anticipated to register a CAGR of 36.6%"

What is the Overview of Gene Therapy for Rare Disease Market?

Gene Therapy has become relevant to rare disease patients and successful gene therapy requires single dose to confer lifelong improvement. Ongoing research and development activities has contributed in market growth. Under development technologies such as cell suspension technology, compendium of standard analytical & bioanalytical methods, cell potentiation technology, plug and play manufacturing process for adeno-associated virus (AAV) serotypes is expected to fruitful the demand for Gene Therapy for Rare Disease market growth.

What are the Recent News of Gene Therapy for Rare Disease Market?

·  In October 2021, U.S. FDA (Food and Drug Administration, five profit organizations and ten pharmaceutical companies has joined forces to develop gene therapies for rare diseases. By standardizing process and leveraging on experience with platform technology, gene therapy product development will be accelerated to allow more timely access to new therapies for needy patients.

Looking for More Information? Download the Free Sample Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/397

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Million & CAGR from 2022 to 2032

Accounted in 2022

US$ 78.4 Million

Estimated to be in 2032

US$ 2087.6 Million

CAGR          

36.6 %

Market Segmentation

By Drug – Approved Drugs and Pipeline Drugs

By Therapeutic Application - Oncology, Neurological Disorders, Ophthalmic Disorders, Hematological Disorders, Immunodeficiency Disorders, Metabolic Disorders, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Customization Scope

Avail of customized purchase options to meet your exact research needs.

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/397

What is Prophecy's Analyst View on Gene Therapy for Rare Disease Market?

New product launch of novel gene therapies for rare disease has become major contribution in target market growth. Growing number of drug approvals, presence of major key players and increase in research & development activities with technological innovation is expected to foster the demand for Gene Therapy for Rare Disease market growth in coming years.

What is gene therapy and how does it work in the treatment of rare diseases?

Gene therapy is a medical treatment that involves modifying a person's DNA to treat or prevent a disease. In rare diseases, gene therapy aims to address the underlying genetic cause of the disease by introducing a functional copy of the defective gene into the patient's cells. This is typically done using viral vectors or non-viral methods. The goal is to produce a functional protein that can correct the genetic defect and achieve a long-lasting therapeutic effect. Although gene therapy for rare diseases is still a developing field with many challenges, it holds great promise for the treatment of genetic disorders that have few or no other treatment options.

What are the Possibilities for Gene Therapy for Rare Disease Market?

  • Increasing investment in gene therapy research and development could lead to the discovery of new treatments for rare genetic disorders.
  • Advances in technology, such as gene editing and improved delivery methods, could make gene therapy more effective and accessible to a wider range of patients.
  • Ongoing clinical trials for gene therapy treatments for rare diseases could lead to FDA approval and commercialization of new therapies.
  • Growing patient demand for personalized medicine and innovative treatments for rare diseases could create a larger market for gene therapy.
  • Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups could accelerate the development and commercialization of gene therapies for rare diseases.
  • Continued regulatory support for gene therapy research and development, including expedited approval pathways, could help bring new therapies to market more quickly.
  • The increasing prevalence of rare genetic disorders and the lack of effective treatments for many of these diseases creates a significant unmet medical need that gene therapy has the potential to address.

What are the future prospects for gene therapy in the treatment of rare diseases, and what new developments can we expect in the field?

The future prospects for gene therapy in the treatment of rare diseases are promising, as new developments in technology and research are making the treatment more effective and accessible. Gene editing technologies such as CRISPR-Cas9 could allow for more precise and targeted treatments, while combination therapies and improved delivery methods are also being explored. It is likely that we will see many new developments in the field in the coming years, leading to increased treatment options for patients with rare genetic disorders.

Looking for More Information? Download the PDF Brochure Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/397

What are key benefits of the Gene Therapy for Rare Disease Market?

  1. Potentially curative: Gene therapy has the potential to cure or significantly improve symptoms of rare genetic disorders by addressing the underlying cause of the disease.
  2. Personalized medicine: Gene therapy is tailored to the specific genetic mutation that causes the rare disease, allowing for a more personalized treatment approach.
  3. Long-lasting effects: Gene therapy has the potential to produce a long-lasting therapeutic effect, reducing the need for ongoing treatment and improving quality of life for patients.
  4. Fewer side effects: Compared to traditional treatments such as chemotherapy, gene therapy is often associated with fewer side effects, making it a more tolerable treatment option for patients.
  5. Potential to treat multiple diseases: Some gene therapies have shown promise in treating multiple rare diseases, increasing the potential impact of these therapies on patient populations.
  6. Increasing investment: Gene therapy research and development is attracting increasing investment, which could lead to the discovery of new therapies for a wider range of rare diseases.

Here are Some Key Reasons to Purchase the Report:

  1. Market growth potential
  2. High unmet medical need
  3. Favorable regulatory environment
  4. Potential for high revenue
  5. Collaboration opportunities
  6. Advancements in technology
  7. Increasing investment in gene therapy R&D
  8. Growing patient demand for personalized medicine
  9. Potential for long-term therapeutic effects
  10. Potential to treat multiple diseases with one therapy.

Report available for Immediate Download:

https://www.prophecymarketinsights.com/market_insight/buy_now/397?licence=6350&report_type=Gene+Therapy+for+Rare+Disease+Market&v1_licence_type=press_id

Key Questions Asked in Report:

  • What is the size and growth potential of the Gene Therapy for Rare Disease Market?
  • What are the major drivers and restraints for the Gene Therapy for Rare Disease Market?
  • What are the key players operating in the Gene Therapy for Rare Disease Market and what are their market shares?
  • What is the current and future market demand for gene therapy for rare diseases?
  • What are the most common rare diseases targeted by gene therapy?
  • What is the future outlook for the Gene Therapy for Rare Disease Market, and what are the potential opportunities and challenges?

Browse Other Related Research Reports from Prophecy Market Insights:

Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%

Cell and Gene Therapy Market accounted for US$ 13.0 billion in 2022 and is estimated to be US$ 62.5 billion by 2032 and is anticipated to register a CAGR of 22.8%

Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR 13.1%.

Drug Discovery Informatics Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 4.9 billion by 2029 and is anticipated to register a CAGR of 8.9%

About Us:                                                                      

Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company's research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.          

To know more        
Contact Us:
Sales Prophecy Market Insights
📞 US toll free: +1 860 531 2574
📞 Rest of world: + 91 7775049802
✉ Email- sales@prophecymarketinsights.com
🌐 Website- www.prophecymarketinsights.com
Follow us on:
LinkedIn | Twitter | Facebook |Youtube 

Logo: https://mma.prnewswire.com/media/2067755/Prophecy_Market_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.